LivsMed has partnered with Sovato on telesurgery. Supply: LivsMed
LivsMed LLC final week mentioned it has accomplished an preliminary public providing, or IPO, on Korea’s KOSDAQ market. It raised about â‚©135.9 billion ($94 million U.S.) at â‚©55,000 per share, bringing its market capitalization to â‚©1.4 trillion, or roughly $1 billion, making it a medical expertise “unicorn.”
The company mentioned it’ll use the proceeds to construct an built-in manufacturing base, fund analysis and improvement, and strengthen associated administration programs to assist world development throughout its product portfolio.
“As we scale globally, we stay targeted on making superior surgical functionality extra accessible,” mentioned Jung Joo Lee, Ph.D., founder and CEO of LivsMed. “An innovation can’t be known as an innovation until it could actually attain the plenty.”
LivsMed develops programs for minimally invasive procedures, and collaborates with physicians worldwide to enhance affected person outcomes and develop entry to superior surgical capabilities. The corporate is headquartered in Seoul and has a U.S. subsidiary in San Diego.
Roadmap consists of robots for the U.S., laparoscopic devices
In July 2025, LivsMed demonstrated the capabilities of its STARK surgical robotic in an early feasibility wet-lab research carried out with telesurgery platform supplier Sovato. Within the demo, the surgeon console was situated in Santa Barbara, Calif., whereas the robotic system was in Chicago, supporting long-distance connectivity.
The STARK robot-assisted surgical system isn’t but accredited to be used and isn’t on the market within the U.S.
LivsMed additionally plans to develop its portfolio of merchandise for minimally invasive surgical procedure. Launched in 2018, ArtiSential is a line of totally articulating handheld laparoscopic devices designed to offer wrist-like dexterity.
The corporate has expanded its platform with ArtiSeal, a 90-degree articulating vessel sealer that it mentioned allows multi-angle entry in confined anatomy.
LivsMed attracts world funding
LivsMed mentioned its IPO drew vital curiosity from main home pension funds and establishments, in addition to massive world monetary establishments headquartered in New York and Boston. Throughout institutional e book constructing, the corporate reported demand of roughly 231-to-1, with abroad participation representing 8.2% of the institutional demand, together with buyers from the U.S., the Center East, and Asia.
On its market debut, LivsMed shares opened greater than 10% above the providing worth, which it mentioned mirrored constructive preliminary market reception. Samsung Securities and Mirae Asset Securities served as joint lead underwriters.
The greenback equivalents offered above used an trade price of â‚©1,445 per $1 as of Dec. 24, 2025.
The put up LivsMed completes Korean IPO to speed up distant robotic surgical procedure appeared first on The Robotic Report.
